Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced a significant milestone: the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for their Omicron JN.1-adapted monovalent COVID-19 vaccine, known as COMIRNATY? JN.1. This recommendation targets active immunization against COVID-19 caused by SARS-CoV-2 for individuals aged 6 months and older. The decision follows guidance from the World Health Organization (WHO) Technical Advisory Group on COVID-19 Vaccine Composition and the European Medicines Agency's Emergency Task Force (ETF), aligning with efforts to enhance vaccine efficacy amidst evolving viral variants, specifically targeting the JN.1 variant for the upcoming 2024-2025 vaccination campaign.

Highlights

The CHMP’s positive opinion marks a critical step towards marketing authorization in the EU, pending final approval from the European Commission. Once approved, the updated vaccine will be swiftly distributed across EU member states, bolstering pandemic response efforts ahead of anticipated seasonal demand.

Enhanced Efficacy and Preparation

Pfizer and BioNTech have proactively manufactured the Omicron JN.1-adapted vaccine in anticipation of increased demand during the fall and winter seasons, aiming to mitigate potential supply chain disruptions. The adaptation process reflects ongoing commitment to addressing emerging variants and maintaining vaccine effectiveness.

Scientific Basis and Regulatory Filings

The CHMP’s recommendation is underpinned by comprehensive clinical, non-clinical, and real-world data demonstrating the safety and efficacy of Pfizer and BioNTech’s COVID-19 vaccines. Specifically, the JN.1-adapted monovalent vaccine has shown significant improvement in targeting multiple Omicron JN.1 sublineages compared to previous adaptations, including KP.2, KP.3, and other circulating variants.

In parallel, Pfizer and BioNTech have initiated regulatory submissions with the U.S. Food and Drug Administration (FDA), aligning with recent FDA recommendations. These filings seek approval for their Omicron KP.2-adapted COVID-19 vaccines for individuals aged 6 months and older, underscoring a commitment to global health preparedness.

Technology and Global Reach

The COMIRNATY? vaccines are based on BioNTech’s innovative mRNA technology, jointly developed and manufactured by Pfizer and BioNTech. BioNTech holds the Marketing Authorization for COMIRNATY? and its adapted formulations in multiple regions, including the United States, European Union, United Kingdom, and other countries. Emergency use authorizations are also in place across various jurisdictions, reflecting broad regulatory acceptance and adherence to stringent safety standards.

Safety and Precautions

Important safety information emphasizes precautions for individuals with known allergies or prior adverse reactions to COVID-19 vaccines. Monitoring for potential rare but severe side effects, such as myocarditis and pericarditis, remains crucial, particularly among adolescent males. Healthcare providers are advised to stay informed about the latest safety data and provide appropriate guidance to vaccine recipients.

For detailed information on safety, usage guidelines, and updates on regulatory approvals, stakeholders are encouraged to refer to official statements from Pfizer and BioNTech, as well as guidance from healthcare authorities.

Data Source: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion-omicron-3